Anticoagulant News and Research

RSS
Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Intermediate dosages of otamixaban reduce acute coronary complications

Intermediate dosages of otamixaban reduce acute coronary complications

Thrombogenics issues business update and half year results

Thrombogenics issues business update and half year results

Joint Commission urges health care leaders to prevent errors by taking the zero-defect approach

Joint Commission urges health care leaders to prevent errors by taking the zero-defect approach

New rule from CMS for improving stroke patient care in hospitals

New rule from CMS for improving stroke patient care in hospitals

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system

Regado Biosciences to commence Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Aryx Therapeutics reports Q2 2009 financials

Aryx Therapeutics reports Q2 2009 financials

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Voice response system useful for monitoring anticoagulant patients

Voice response system useful for monitoring anticoagulant patients

New method to estimate bleeding risk in heart attack patients

New method to estimate bleeding risk in heart attack patients

Complementary and alternative medicines can be safe, effective for kids

Complementary and alternative medicines can be safe, effective for kids

Discovery of link between atrial fibrillation and increased risk of death in diabetic patients

Discovery of link between atrial fibrillation and increased risk of death in diabetic patients

Kidney disease increases risk of stroke in patients with atrial fibrillation

Kidney disease increases risk of stroke in patients with atrial fibrillation

Kidney disease affects response to anticoagulant drug warfarin

Kidney disease affects response to anticoagulant drug warfarin

Study reveals high level of adverse drug reactions in hospitals

Study reveals high level of adverse drug reactions in hospitals

FDA approves orphan drug ATryn anticoagulant

FDA approves orphan drug ATryn anticoagulant

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.